Analysts Set Charles River Laboratories International, Inc. (NYSE:CRL) PT at $253.23

Charles River Laboratories International, Inc. (NYSE:CRL) has been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $253.23.

CRL has been the subject of a number of recent research reports. Citigroup boosted their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. UBS Group upped their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Robert W. Baird boosted their price objective on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Guggenheim lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Finally, Argus upped their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, March 18th.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at $3,437,635. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Several large investors have recently modified their holdings of the business. Moneta Group Investment Advisors LLC bought a new position in Charles River Laboratories International in the 4th quarter worth approximately $298,877,000. Meritage Group LP bought a new position in shares of Charles River Laboratories International in the third quarter worth $173,174,000. Price T Rowe Associates Inc. MD grew its position in shares of Charles River Laboratories International by 35.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock valued at $505,821,000 after purchasing an additional 653,790 shares in the last quarter. Norges Bank bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at $97,675,000. Finally, Point72 Asset Management L.P. lifted its holdings in Charles River Laboratories International by 499.1% during the 4th quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock worth $87,228,000 after purchasing an additional 307,398 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 1.1 %

Shares of NYSE CRL opened at $229.90 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The firm has a market cap of $11.84 billion, a PE ratio of 24.96, a P/E/G ratio of 1.85 and a beta of 1.40. The company’s fifty day simple moving average is $253.47 and its 200 day simple moving average is $220.92. Charles River Laboratories International has a 12-month low of $161.65 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter in the prior year, the firm earned $2.98 EPS. The business’s revenue was down 7.9% on a year-over-year basis. As a group, sell-side analysts forecast that Charles River Laboratories International will post 11.01 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).